Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial (2018)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1001/jamaoncol.2018.0060
- Subjects: NEOPLASIAS MAMÁRIAS; ANTINEOPLÁSICOS; RECEPTORES HORMONAIS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Jama oncology
- ISSN: 2374-2437
- Volume/Número/Paginação/Ano: v. 4, n. 7, p. 977-984, 2018
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
ROYCE, Melanie e HEGG, Roberto. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, v. 4, n. 7, p. 977-984, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2018.0060. Acesso em: 18 abr. 2024. -
APA
Royce, M., & Hegg, R. (2018). Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, 4( 7), 977-984. doi:10.1001/jamaoncol.2018.0060 -
NLM
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2024 abr. 18 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060 -
Vancouver
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2024 abr. 18 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060 - Cancer de ovario
- Vias e esquemas de administração dos hormônios esteróides
- Eficácia, tolerabilidade e controle de ciclo de um contraceptivo oral sem estrogênio contendo 30 mcg de levonorgestrel (minipílula)
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer
- First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial
- Galactorreia: sindrome hiperprolactinemica
- Como diagnosticar e tratar sindrome do climaterio
- Hormonioterapia de reposicao e cancer de mama
Informações sobre o DOI: 10.1001/jamaoncol.2018.0060 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas